Literature DB >> 28798215

Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation.

M Mauda-Havakuk1,2, B Shofty3,4, S Ben-Shachar1, L Ben-Sira1,2, S Constantini1,4, F Bokstein1,5.   

Abstract

BACKGROUND AND
PURPOSE: Neurofibromatosis type 1 is a common tumor predisposition syndrome. The aim of this study was to characterize the radiologic presentation of patients with neurofibromatosis type 1 with widespread spinal disease and to correlate it to clinical presentation and outcome.
MATERIALS AND METHODS: We conducted a historical cohort study of adult patients with neurofibromatosis type 1 with spinal involvement. Longitudinal clinical evaluation included pain and neurologic deficits. Radiologically, spinal involvement was classified according to a novel classification system, and a radiologic risk score was calculated.
RESULTS: Two hundred fifty-seven adult patients with neurofibromatosis type 1 are followed in our center. Thirty-four of these patients qualified for inclusion in this study. Three independent factors were found to be associated with increased risk for neurologic deficit: 1) bilateral tumors at the same level in the cervical region that approximated each other, 2) paraspinal tumors at the lumbar region, and 3) intradural lesions. On the basis of these factors, we calculated a combined risk score for neurologic deficits for each patient. We found a clear correlation between patient status and the calculated radiologic risk score. Patients with neurologic deficits were found to have a higher risk score (9 ± 8.3) than patients without neurologic deficits (2.5 ± 2.9, P < .05). Patients who progressed during the follow-up period had significantly higher scores at presentation than patients with stable conditions (9.9 ± 8.73 versus 3.9 ± 5.3, respectively; P < .05).
CONCLUSIONS: In this series, neurologic deficit is correlated with tumor burden and subtype. We found no direct correlation with tumor burden and pain. Our novel radiologic classification scoring system may be used to predict increased risk for neurologic morbidity.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2017        PMID: 28798215      PMCID: PMC7963632          DOI: 10.3174/ajnr.A5338

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  14 in total

1.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

Review 2.  Neurofibromatosis type 1: spinal manifestations of a systemic disease.

Authors:  Carlos S Restrepo; Roy F Riascos; Ami A Hatta; Rafael Rojas
Journal:  J Comput Assist Tomogr       Date:  2005 Jul-Aug       Impact factor: 1.826

3.  Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype.

Authors:  N J Patronas; N Courcoutsakis; C M Bromley; G L Katzman; M MacCollin; D M Parry
Journal:  Radiology       Date:  2001-02       Impact factor: 11.105

4.  Surgical management of cervical spine manifestations of neurofibromatosis Type 1: long-term clinical and radiological follow-up in 22 cases.

Authors:  Faisal S Taleb; Abhijit Guha; Paul M Arnold; Michael G Fehlings; Eric M Massicotte
Journal:  J Neurosurg Spine       Date:  2011-01-14

5.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

6.  Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging.

Authors:  Rosa Nguyen; Eva Dombi; Srivandana Akshintala; Andrea Baldwin; Brigitte C Widemann
Journal:  J Neurooncol       Date:  2014-10-08       Impact factor: 4.130

7.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 8.  The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features.

Authors:  M Ruggieri; A Polizzi; A Spalice; V Salpietro; R Caltabiano; V D'Orazi; P Pavone; C Pirrone; G Magro; N Platania; S Cavallaro; M Muglia; F Nicita
Journal:  Clin Genet       Date:  2014-11-22       Impact factor: 4.438

9.  Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors.

Authors:  Ole Goertz; Stefan Langer; Daniela Uthoff; Andrej Ring; Ingo Stricker; Andrea Tannapfel; Hans-Ulrich Steinau
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

10.  Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.

Authors:  Regina I Jakacki; Eva Dombi; Seth M Steinberg; Stewart Goldman; Mark W Kieran; Nicole J Ullrich; Ian F Pollack; Anne Goodwin; Peter E Manley; Jason Fangusaro; Rudy Allen; Brigitte C Widemann
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more
  2 in total

Review 1.  Spinal manifestations of Neurofibromatosis type 1.

Authors:  Ben Shofty; Ori Barzilai; Morsi Khashan; Zvi Lidar; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-20       Impact factor: 1.475

2.  The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.

Authors:  Sadhana Jackson; Eva H Baker; Andrea M Gross; Patricia Whitcomb; Andrea Baldwin; Joanne Derdak; Cecilia Tibery; Jennifer Desanto; Amanda Carbonell; Kaleb Yohay; Geraldine O'Sullivan; Alice P Chen; Brigitte C Widemann; Eva Dombi
Journal:  Neurooncol Adv       Date:  2020-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.